Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



BC: Articoli scritti da L. Murgia

Il microRNA-135b nella caratterizzazione molecolare del carcinoma della mammella “triplo negativo”
miRNA-135b in molecular characterization of triple-negative breast cancer (TNBC)
G. Pira  |  L. Murgia  |  F. Sanges  |  P. Uva  |  P. Cossu-Rocca  |  F. Loi  |  S. Orrù  |  M.R. Muroni  |  C. Carru  |  A. Angius  |  M.R. De Miglio  | 
<p>TNBC accounts for 12-24% of all mammary cancers (BC). Its clinical and genetic heterogeneity and the lack of unambiguous molecular targets contribute to the scarcity of therapeutic options for this BC variant. Recently, the BC molecular biology has entered in the era of microRNAs (miRNA), a class of small highly conserved regulatory endogenous non-coding RNAs, which control complicated signaling pathways, governing cell cycle, proliferation, differentiation, apoptosis, etc., and whose deregulation contributes to the tumour development. Our goal was to improve the knowledge of TNBC biology analyzing the miRNA expression profile and to identify new potential prognostic and predictive biomarkers. We conducted a human miRNome analysis by TaqMan Low Density Array comparing different TNBC subtypes, defined by immunohistochemical basal markers, such as epidermal growth factor receptor and cytokeratin 5/6. Quantitative reverse transcription polymerase chain reaction confirmed differential expression of miRNA. We identified a single miRNA signature given by miR-135b expression levels, which allowed the distinction of TNBC with and without basal-like phenotype. Our study sheds light on the molecular complexity of TNBC and shows for the first time that miR-135b expression is strictly related to TNBC basal-like molecular subtype, acting as an oncogene in the tumor pathogenesis.</p>
Biochimica Clinica ; 41(3) 239-244
Contributi scientifici - Scientific papers
 
Pemfigoide bolloso in una paziente di 106 anni
Bullous pemphigoid in a 106-years old female
V. Ventura  |  M. Posadinu  |  M. Deiana  |  A. Baralla  |  S. Pasella  |  L. Murgia  |  S. Pinna  |  E.  Canu  |  A. Zinellu  |  S. Sotgia  |  C. Carru  |  L. Deiana  | 
<p>Bullous pemhigoid (BP) is an autoimmune subepidermal blistering&nbsp;disease, usually occurring in the elderly. In Europe the incidence of BP has doubled in the last 10 years. The disease&nbsp;has a chronic relapsing course and a relatively benign prognosis. An increasing number of publications report altered&nbsp;expression of a number of cytokines. However, at the present it is not possible to establish a specific role for them in&nbsp;the disease. We report a case of a centenarian woman with a BP occurrence in otherwise optimal health conditions.&nbsp;Besides the usual biochemical investigations, plasma concentrations of a number of cytokines were evaluated during&nbsp;the disease course (relapse and remission). The majority of the measured cytokines were elevated in the active phase&nbsp;of the disease and returned to values similar to those presented by a group of apparently healthy subjects of similar&nbsp;age during the remission. This case could be useful to better understand the role of cytokines in autoimmune skin&nbsp;diseases of the aging.</p>
Biochimica Clinica ; 39(2) 152-156
Casi clinici - Case report
 
Interleuchine e necrolisi tossica epidermica
Interleukins and toxic epidermal necrolysis (TEN)
V. Ventura  |  A. Posadinu  |  M. Deiana  |  A. Baralla  |  S. Pasella  |  L. Murgia  |  S. Pinna  |  E.  Canu  |  A. Marchisio  |  A. Zinellu  |  C. Carru  |  L. Deiana  | 
<p>TEN is a rare disease characterized by the separation of skin&nbsp;and mucous membranes from the derma. The reported clinical case refers to an adult female hospitalized at the&nbsp;Burns Unit after allopurinol prescription. During hospitalization the patient underwent the therapeutic protocol&nbsp;established at the Burns Unit including intravenus immunoglobulin administration and plasmapheresis. At the end of&nbsp;therapy a clinical improvement of both local and global conditions was observed. During the course of disease, we&nbsp;measured plasma concentrations of a number of cytokines. Measurements were performed using commercially&nbsp;available multiplex bead-based sandwich immunoassays (Biorad). We found a marked decrease in concentrations of&nbsp;interleukin (IL)-6, interferon -induced protein (IP)-10 e IL-13 at various stages of apheresis therapy, particularly&nbsp;pronounced for IP-10. We also found a normalization of IL-6 and IP-10 concentrations during the follow-up. In&nbsp;addition, very high concentrations of the same cytokines in the plasma effluent after apheresis were observed.&nbsp;Although obtained in a single case, our results suggest a correlation between plasma concentrations of cytokines and&nbsp;the clinical course of TEN. It can be postulated that this approach could serve as a guide for future research in the&nbsp;development of targeted therapy based on the etiopathogenesis of TEN.</p>
Biochimica Clinica ; 38(1) 65-69
Casi clinici - Case report